The Alpha-1-Antitrypsin Quantitative Test measures levels of alpha-1-antitrypsin (AAT), a protein that protects the lungs and liver from damage. Low levels may indicate alpha-1-antitrypsin deficiency, a genetic disorder linked to emphysema, COPD, and liver disease. Doctors use this test to investigate unexplained lung or liver problems, confirm hereditary AAT deficiency, and guide treatment or monitoring strategies for long-term health management.

The Alpha-1 Antitrypsin Random Feces Test measures levels of alpha-1 antitrypsin, a protein that normally remains in the bloodstream. Elevated amounts in stool suggest protein-losing enteropathy, intestinal inflammation, or gastrointestinal conditions that impair absorption. By evaluating protein loss through the digestive tract, this test helps assess intestinal integrity and overall digestive health.

The Alpha-1 Antitrypsin 24 Hour Feces Test measures levels of alpha-1 antitrypsin in stool to evaluate protein loss through the gastrointestinal tract. Elevated results indicate protein-losing enteropathy, a condition where proteins leak into the intestines. This test provides valuable insight into unexplained edema, malnutrition, or chronic diarrhea, helping clinicians assess digestive health and guide evaluation of protein metabolism.

The LH-2 Liver Health panel is a comprehensive suite of tests designed to evaluate liver function, identify liver damage, and screen for specific liver disorders. This panel includes Quantitative Alpha-1-Antitrypsin, Alpha-Fetoprotein and AFP-L3, Fractionated Bilirubin (Direct, Indirect, and Total), Ceruloplasmin, Comprehensive Metabolic Panel, Gamma Glutamyl Transferase, Iron and Total Iron Binding Capacity, Lactate Dehydrogenase, and Prothrombin Time with INR. Each of these tests offers valuable insights into liver health, potential liver disease, and the liver's capacity to perform its vital functions.

The LH-3 Liver Health panel is an extensive diagnostic tool designed to provide a comprehensive assessment of liver health. This panel includes a wide range of tests that evaluate liver function, screen for liver infections, and assess liver damage. It comprises Quantitative Alpha-1-Antitrypsin, Alpha-Fetoprotein and AFP-L3, Fractionated Bilirubin, Ceruloplasmin, Comprehensive Metabolic Panel, Copper, Gamma Glutamyl Transferase, Hepatitis A, B, and C antibodies and antigens, Iron and Total Iron Binding Capacity, Lactate Dehydrogenase, and Prothrombin Time with INR.

The LH-4 Liver Health panel is the most comprehensive suite of tests tailored to provide an in-depth evaluation of liver health, function, and the presence of liver diseases, including liver cancer and viral hepatitis. It encompasses a broad spectrum of markers, from liver enzymes and proteins to specific tests for genetic conditions, liver cancer markers, and comprehensive screening for hepatitis infections.

The Alpha-Fetoprotein (AFP) and AFP-L3 Test measures total AFP and the AFP-L3 fraction, which is more specific for liver cancer risk. Elevated AFP may indicate liver disease, germ cell tumors, or hepatitis, while AFP-L3 is strongly associated with hepatocellular carcinoma (HCC). Doctors order this test to assess liver function, screen high-risk patients, and monitor cancer treatment. Results provide critical insight into liver health and cancer detection.

The LH-1 Liver Health panel is a focused diagnostic tool designed to assess the overall health and functionality of the liver. This panel includes tests for Gamma Glutamyl Transferase (GGT), Hepatic Function Panel, Lactate Dehydrogenase (LDH), and Prothrombin Time with INR, offering a snapshot of liver function, potential liver damage, and the liver's ability to synthesize proteins necessary for blood clotting.